ONCO-INNOVATIONS LTD

Onco‑Innovations advances ONC010, a nanoparticle‑formulated PNKP inhibitor, toward human trials with new metabolic studies, positioning it as a leader in DNA‑repair oncology therapies.

Onco‑Innovations launches three‑species metabolism studies for ONC010, a nanoparticle‑based PNKP inhibitor, to support PK modelling, dose‑selection and IND strategy.

Onco‑Innovations raises $5 M to scale up ONC010, a DNA‑damage potentiator, and launch its SynoGraph AI‑driven platform, boosting its path to clinical trials.

Onco‑Innovations Ltd’s stock swings reflect the high‑risk, high‑reward nature of biotech, yet its cutting‑edge cancer therapies promise a breakthrough in personalized medicine.

Onco-Innovations Limited has closed a private placement, raising $2 million through the issuance of 1.4 million units at $1.40 per unit, which will be used to support ongoing research and development of its oncology pipeline.

Onco-Innovations Ltd has made significant strides in oncology and data analytics through strategic partnerships and financial restructuring, positioning the company for long-term growth and potential returns on investment.